Can You Take NMN or NR With Opioids Like Oxycodone, Hydrocodone, or Tramadol?

Why This Interaction Question Matters

Millions of Americans take opioid prescriptions while simultaneously using NAD+ precursor supplements. In 2021, U.S. providers wrote approximately 143.4 million opioid prescriptions, and the NMN/NR supplement market has grown rapidly since nicotinamide mononucleotide received "new dietary ingredient" (NDI) notification acceptance. Patients rarely volunteer supplement use to their prescribers. One survey published in JAMA Internal Medicine found that only 33% of supplement users disclosed this information to their physicians.

This gap matters because opioids carry a narrow therapeutic index. Small shifts in drug metabolism can mean the difference between adequate analgesia and dangerous respiratory depression. The question is whether NMN or NR can produce such shifts. The short answer: we lack definitive human data, but the biochemical plausibility is real enough to warrant caution. Here is what the pharmacology tells us.

Pharmacology of NMN and NR: How NAD+ Precursors Are Metabolized

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both converted intracellularly to NAD+ through distinct but converging pathways. NR enters cells via equilibrative nucleoside transporters and is phosphorylated by nicotinamide riboside kinases (NRK1/NRK2) to form NMN, which is then adenylylated to NAD+ by NMNAT enzymes [1]. NMN itself can be converted to NR extracellularly by CD73 before cellular uptake, or may enter cells directly via the Slc12a8 transporter identified in murine models [2].

Neither NMN nor NR undergoes significant phase I (CYP450) metabolism directly. Their primary metabolic fate is conversion to NAD+ and subsequent participation in redox reactions, sirtuin-mediated deacetylation, and PARP-dependent DNA repair. The downstream metabolite, nicotinamide (NAM), is metabolized hepatically by nicotinamide N-methyltransferase (NNMT) and to a lesser extent by CYP2E1 [3].

This is the first relevant connection to opioid metabolism. NAD+ itself serves as a cofactor for multiple hepatic processes, and elevated NAD+ levels may influence CYP450 enzyme expression through sirtuin-mediated pathways. A 2019 study in Hepatology demonstrated that SIRT1 activation (driven by NAD+ availability) upregulated CYP3A4 promoter activity in human hepatocytes [4]. The clinical significance of this finding remains unquantified in living patients.

How Opioids Are Metabolized: CYP3A4 and CYP2D6 Pathways

Each of the three opioids in question relies on hepatic CYP450 enzymes for biotransformation, but the specific pathways and active metabolites differ.

Oxycodone is primarily metabolized by CYP3A4 to noroxycodone (the major metabolite, largely inactive) and by CYP2D6 to oxymorphone (a minor but highly potent metabolite with approximately 14-fold greater mu-opioid receptor affinity than the parent compound) [5]. The FDA label for oxycodone warns that CYP3A4 inhibitors can increase plasma concentrations of oxycodone, raising the risk of fatal respiratory depression.

Hydrocodone undergoes O-demethylation by CYP2D6 to hydromorphone (active, more potent) and N-demethylation by CYP3A4 to norhydrocodone (less active). CYP2D6 poor metabolizers produce less hydromorphone and may experience reduced analgesic effect, while ultra-rapid metabolizers face toxicity risk [6].

Tramadol is the most metabolically complex of the three. CYP2D6 converts it to O-desmethyltramadol (M1), which has 200-fold greater mu-opioid affinity than the parent drug [7]. CYP3A4 produces the N-desmethyl metabolite (M2), which is largely inactive. Tramadol also inhibits serotonin and norepinephrine reuptake, adding a non-opioid analgesic mechanism and a seizure/serotonin syndrome risk that oxycodone and hydrocodone do not share.

The common thread: all three drugs depend on CYP3A4, CYP2D6, or both. Any compound that modulates these enzymes could alter opioid exposure.

The Theoretical Interaction Mechanism: NAD+, Sirtuins, and CYP Expression

No published human pharmacokinetic study has co-administered NMN or NR with any opioid. That absence is itself clinically relevant information. The theoretical concern rests on a chain of biochemical reasoning.

Exogenous NMN/NR supplementation raises whole-blood NAD+ levels. A randomized, double-blind trial by Yi et al. (2023, New England Journal of Medicine Evidence) showed that 12 weeks of NMN 300 mg/day increased blood NAD+ by approximately 38% compared to placebo in middle-aged adults [8]. A separate RCT of NR 1,000 mg/day by Martens et al. (2018) documented a 60% increase in NAD+ metabolome levels in healthy older adults [9].

Elevated NAD+ fuels sirtuin activity. SIRT1, the most studied NAD+-dependent deacetylase, regulates the pregnane X receptor (PXR) and constitutive androstane receptor (CAR), both of which are transcriptional activators of CYP3A4 and CYP2D6 gene expression [10]. In preclinical hepatocyte models, pharmacological SIRT1 activation increased CYP3A4 mRNA expression by 1.8- to 2.4-fold [4].

If this effect translates to humans at supplement-achievable NAD+ elevations, the clinical consequence would be increased CYP3A4 activity, which could:

• Reduce oxycodone plasma levels (increased clearance to inactive noroxycodone), potentially decreasing pain control
• Reduce tramadol parent compound levels while simultaneously increasing CYP2D6-mediated conversion to the more potent M1 metabolite, a dual-risk scenario
• Alter the ratio of hydrocodone to hydromorphone in unpredictable ways depending on whether CYP3A4 induction outpaces CYP2D6 modulation

The word "could" is doing significant work in those bullet points. No one has measured these effects in patients taking both compounds.

Severity Rating and Clinical Risk Stratification

Standard drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list NMN or NR as interacting agents with any opioid. This reflects a data vacuum, not a confirmed safety signal.

Based on available pharmacologic evidence, the interaction risk can be stratified as follows:

Low risk (most patients): Healthy adults taking standard NMN doses (250 to 500 mg/day) alongside short-term, low-dose opioid prescriptions (e.g., post-dental oxycodone 5 mg for 3 days). The duration of co-exposure is too brief for meaningful CYP induction, and NAD+ elevation at these doses is modest.

Moderate theoretical risk: Patients on chronic opioid therapy (daily oxycodone, hydrocodone, or tramadol for 30+ days) who simultaneously take high-dose NMN (500 to 1,000 mg/day) or NR (1,000 mg/day) for extended periods. Sustained NAD+ elevation could produce chronic low-grade CYP3A4 induction, gradually shifting opioid pharmacokinetics.

Higher theoretical risk: CYP2D6 ultra-rapid metabolizers taking tramadol with high-dose NR. If NR-mediated NAD+ elevation further enhances CYP2D6 transcription even modestly, these patients could generate toxic M1 concentrations. The FDA black-box warning on tramadol already contraindicates use in known CYP2D6 ultra-rapid metabolizers [11].

NAD+ Precursors and Opioid-Induced Neuroinflammation: A Separate Pathway

Beyond CYP metabolism, a growing preclinical literature suggests NAD+ repletion may directly modulate opioid pharmacodynamics through neuroinflammatory and epigenetic pathways.

Chronic opioid exposure depletes neuronal NAD+ via PARP hyperactivation driven by oxidative DNA damage. A 2020 study in Neuropsychopharmacology found that morphine-treated mice showed a 42% reduction in brain NAD+ levels after 7 days, and that NMN supplementation (500 mg/kg IP) partially reversed tolerance development and reduced withdrawal severity scores by 35% [12]. Hamity et al. (2020) demonstrated similar findings with NR in a rat model of oxycodone dependence, showing that NAD+ repletion attenuated glial activation in the periaqueductal gray [13].

These are animal studies at supraphysiologic doses. They do not establish that oral NMN at human supplement doses produces the same effects. But they raise a pharmacodynamic consideration that is distinct from the CYP concern: if NAD+ precursors genuinely reduce opioid tolerance, patients might experience enhanced opioid effect at previously tolerated doses after starting NMN/NR supplementation.

Dr. Charles Brenner, who discovered the NR kinase pathway, has stated: "NAD+ precursors are not inert vitamins. They reprogram cellular metabolism in ways we are only beginning to catalog. Co-administration with drugs that have narrow therapeutic windows requires the same scrutiny we apply to any potential drug-nutrient interaction" [14].

Monitoring Recommendations for Co-Administration

Until human interaction data exist, clinicians managing patients who take both NMN/NR and opioids should consider the following monitoring approach.

Before starting NMN/NR in a patient on chronic opioids:

• Document current opioid dose, pain scores, and any signs of tolerance
• Consider CYP2D6 genotyping if tramadol is the prescribed opioid (this is already recommended by CPIC guidelines independent of NMN/NR use) [15]
• Record baseline sedation and respiratory parameters

During the first 4 weeks of co-administration:

• Reassess pain control at 2 and 4 weeks. A decline in analgesic efficacy could suggest CYP3A4 induction
• Monitor for unexpected sedation or respiratory depression, which could suggest reduced opioid clearance or pharmacodynamic enhancement
• If the patient is on tramadol, watch for signs of serotonin excess (agitation, tremor, hyperreflexia, diaphoresis)

Ongoing:

• Reassess at each opioid renewal. If the patient has dose-escalated since starting NMN/NR, consider whether altered metabolism (rather than disease progression) may be contributing
• If NMN/NR is discontinued after chronic use, monitor for opioid toxicity, as CYP expression may revert to baseline while the opioid dose remains elevated

The 2022 CDC Clinical Practice Guideline for Prescribing Opioids recommends reassessing benefits and risks within 1 to 4 weeks of starting opioid therapy and at least every 3 months thereafter [16]. Adding a new supplement that may alter drug metabolism represents a reasonable trigger for an interim reassessment.

Patient Counseling Points

Patients should receive three specific instructions.

First: do not start or stop NMN/NR without informing the prescriber who manages your opioid. The supplement is legal and available without prescription, but that does not mean it is free of drug interaction potential.

Second: do not adjust your opioid dose based on perceived changes in pain control after starting NMN/NR. If your pain medication seems less effective, contact your prescriber rather than taking additional doses.

Third: if you take tramadol, be aware of seizure and serotonin syndrome warning signs (muscle rigidity, fever above 38°C, rapid heart rate, confusion). While NMN/NR has not been shown to worsen these risks, the interaction space is unstudied. Report any new neurological symptoms immediately.

Dose-Adjustment Guidance

No evidence-based dose adjustment protocol exists for this combination. The absence of data does not permit a specific recommendation. The American Association of Clinical Endocrinology (AACE) has not issued guidance on NAD+ precursor supplementation in the context of concurrent prescription medications [17].

A conservative clinical approach: if a patient on stable chronic opioid therapy wishes to start NMN or NR, begin the supplement at the lowest marketed dose (typically NMN 250 mg/day or NR 300 mg/day) and titrate slowly over 4 to 6 weeks while monitoring analgesic efficacy and adverse effects. This mirrors the "start low, go slow" principle applied to any new agent introduced into a polypharmacy regimen.

Patients on methadone for opioid use disorder deserve special mention. Methadone is metabolized by CYP3A4, CYP2B6, and CYP2D6, has an extremely long and variable half-life (8 to 59 hours), and carries a QTc prolongation risk. Any supplement with theoretical CYP3A4 induction potential should be approached with particular caution in this population, and supplementation should only proceed under direct medical supervision.

The Regulatory Gap: Supplements vs. Drugs

NMN and NR occupy an uncertain regulatory space. NMN was briefly the subject of an FDA enforcement action questioning its status as a dietary supplement versus an investigational new drug (due to Metro International Biotech's IND filing), though products remain widely sold. NR (as Niagen) holds FDA GRAS status for food use and self-affirmed NDI status as a supplement [18].

Neither compound has undergone the formal drug interaction studies (in vitro CYP inhibition/induction panels, clinical DDI trials with index substrates) that the FDA requires of approved drugs. For a conventional pharmaceutical, the agency mandates in vitro CYP3A4 induction testing during IND-stage development per the 2020 FDA Drug Interaction Guidance. Supplements bypass this requirement entirely.

This means the "no known interaction" label that patients encounter on supplement bottles reflects an absence of testing, not a confirmation of safety.